Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Elezoglou, Antonia V ^a   Kafasi, Nikolitsa ^a   Kaklamanis, Phaedon H ^b   Theodossiadis, Panagiotis G ^a   Kapsimali, Violetta ^a   Choremi, Eleni ^a   Vaiopoulos, George ^a   Sfikakis, Petros P ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

^c NONE   (Greece)

Author keywords

Anti beta2 glycoprotein I; Anti cardiolipin; Anti cyclic citrullinated peptide; Anti dsDNA; Anti La; Anti RNP; Anti Ro; Anti Sm; Antineutrophil cytoplasmic; Antinuclear antibodies; Be het's disease; Infliximab; Rheumatoid factor

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DNA ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; LA ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; DOUBLE STRANDED DNA ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LUPUS LIKE SYNDROME; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPEATED DRUG DOSE; THROMBOSIS; AGE DISTRIBUTION; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BEHCET SYNDROME; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447345091     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. KAKLAMANI VG, VAIOPOULOS G, KAKLAMANIS PG: Behçet's disease. Semin Arthritis Rheum 1998; 27: 197-217.
2. SFIKAKIS PP: BeAçet's Disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 2002; 61 (Suppl. 2): 51-3.
3. YAMASHITA N, KANEOKA H, KANEKO S et al.: Role of γδ T lymphocytes in the development of Behçet's Disease. Clin Exp Immunol 1997; 107: 241-7.
4. ELEZOGLOU AV, SFIKAKIS PP, VAIOPOULOS G, KAPSIMALI V, KAKLAMANIS PG: Serum levels of soluble TNF-α Receptor-II (p75), circulating γδ T-cells and Adamantiades-Behçet's disease activity. Adv Exp Med Biol 2003; 528: 261-5.
5. SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS PH, MARKOMICHELAKIS N: Rapid remission of sight-threatening panuveitis in Adamantiades-Behçet's Disease with Infliximab. Lancet 2001; 358: 295-6.
6. SFIKAKIS PP, KAKLAMANIS PH, ELEZOGLOU A et al.: Effects of Infliximab in patients with Adamantiades-Behçet's Disease and recurrent, sight-threatening ocular inflammation. Ann Intern Med 2004; 140: 406-8.
7. KATSIARI CG, THEODOSSIADIS PG, KAKLAMANIS PH, MARKOMICHELAKIS N, SFIKAKIS PP: Successful long-term treatment of refractory Adamantiades-Behçet's Disease with infliximab: Report of two patients Adv Exp Med Biol 2003; 528: 551-5.
8. OHNO S, NAKAMURA S, HORI S et al.: Efficacy, safety and pharmacokinetics of multi- ple administration of Infliximab in Behçet's Disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362.
9. TUGAL-TUTKUN I, MUDUN A, URGANCIOGLU M et al.: Efficacy of Infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. An open-label trial. Arthritis Rheum 2005; 52: 2478-84.
10. LOUIS M, RAUCH J, ARMSTRONG M, FITZCHARLES MA: Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003; 30: 2557-62.
11. JONSDOTTIR T, FORSLID J, VAN VOLLENHOVEN A et al.: Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63: 1075-8.
12. DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-23.
13. ALLANORE Y, SELLAM J, BATYEUX F, JOB DESLANDRE C, WEILL B, KAHAN A: Induction of autoantibodies in refractory rheumatoid arthritis by Infliximab. Clin Exp Rheumatol 2004; 22: 756-8.
14. DE RYCKE L, BAETEN D, KRUITHOF E, VAN DEN BOSCH F, VEYS EM, DE KEYSER F: The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: Biological and clinical implications. Lupus 2005; 14: 931.
15. YAZDAKI-BIUKI B, WOHLFART K, MULABECIROVIC A et al.: Long term treatment of psoriatic arthritis with Infliximab. Ann Rheum Dis 2004; 63: 1531-2.
16. GARCIA-PLANELLA E, DOMENECH E, ESTEVE-COMAS M et al.: Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 351-4.
17. INTERNATIONAL STUDY GROUP FOR BEÇHET'S DISEASE: Criteria for diagnosis of Behçet's Disease. Lancet 1990; 335: 1078-80.
18. SFIKAKIS PP, KOLLIAS G: Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheum 2003; 15: 380-6.
19. NIKAS SN, ALAMANOS Y, VOULGARI PV, PLIAKOU XI, PAPADOPOULOS CG, DROSOS AA: Infliximab treatment in ankylosing spoAdylitis: an observational study. Ann Rheum Dis 205; 64: 940-2.
20. CHARLES PJ, SMEENK R J, DE JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled tri- als. Arthritis Rheum 2000; 43: 2383-90.
21. ERIKSSON C, ENGSTRAND S, SUNDQVIST KG, RANTAPAA-DAHLQVIST S: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy. Ann Rheum Dis 2005; 64: 403-7.
22. ZOUBOULIS CC, BUTTNER P, TEBBE B, ORFANOS CE: Anticardiolipin antibodies in Adamantiades- Behçet's disease. Br J Dermatol 1993; 128: 281-4.
23. EL-AGEB EM, AL-MAINI MH, AL-SHUKAILY AK, AL-FARSI Y, RICHENS ER: Clinical features of Behçet's disease in patients in the Sultanate of Oman; the significance of antiphospholipid antibodies. Rheumatol Int 2002; 21: 176-81.
24. MAINI RN, BREEDVELD FC, KALDEN JP et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.